Abbott Laboratories (ABT) Stock Price Today
Aura AI Summary
Key Stats
- $166.17BMARKET_CAP
- -VOLUME
- HealthSECTOR
- $136.62FIFTY_TWO_WEEK_HIGH
- $82.57FIFTY_TWO_WEEK_LOW
- -TYPICAL_HOLD_TIME
- $192.92BENTERPRISE_VALUE
- 2.64%DIVIDEND_YIELD
- -TRADING_ACTIVITY
Track Abbott Laboratories (ABT) stock price today on Pluang, updated in real time with live charts and market data. Over the past 52 weeks, Abbott Laboratories has traded between a low of $82.57 and a high of $136.62, highlighting its annual price range. Buy and sell Abbott Laboratories shares on Pluang with fractional shares and real-time market data — safe and OJK-regulated.
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Most Recent News
Kering investigated for not refunding tariff-driven price hikes after Supreme Court ruling
Edelson Lechtzin LLP is investigating Kering S.A. for potentially keeping tariff-related price increases on luxury brands like Gucci and Saint Laurent without refunding consumers after the U.S. Supreme Court ruled the tariffs unlawful in February 202...

Enbridge downgraded to Hold as recent gains reflect growth already priced in, limiting upside.
Enbridge (ENB) has been downgraded to a Hold rating because its recent share price increase has already factored in much of its growth potential. The company’s key projects, including the 1.6 GW Cowboy Project with Meta and expansions in storage and ...

VICI Properties offers 36% upside with strong balance sheet and 6.62% dividend yield amid market fears.
VICI Properties is currently trading at a low price-to-AFFO ratio of 11.24x, well below its historical average, suggesting a potential 36% price increase as the valuation normalizes. The company maintains a strong financial position with conservative...
